Pages
- exemple
- SPL5B
- About IPF
- About Mucins
- SPL5AC
- Our Platform
- Presentations
- Publications
- נושמים לרווחה: חוקרים ישראלים זיהו מולקולה שתסייע בפיתוח תרופה חדשה לחולי סיסטיק פיברוזיס מחקר שנעשה על ידי צוות ישראלי ובינלאומי מצא מולקולה שתסייע לפיתוח טיפול חדש לחולי סיסטיק פיברוזיס, שיוכל לשפר באופן משמעותי את איכות חייהם של הלוקים במחלה הגנטית
- About Muco – Obstructive Lung (Pulmonary) Diseases
- Additional Opportunities
- SPL16
- SPL23
- SPL84
- SpliSense Board of Directors
- Career
- Home-2
- About Cystic Fibrosis
- Pipeline
- About Antisense Oligonucleotides (ASOs)
- SpliSense Team
- Blog
- Contact Us
- Who We Are
- Home
- Thank you
- Sitemap
- Privacy Policy
- Пример страницы
Categories
Posts
- CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations
- SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis
- SpliSense is excited to share its most recent press release, announcing the successful completion a first-in-human, Phase 1 clinical trial of SPL84, the company’s lead anti sense oligonucleotide (ASO) product for the treatment of patients with CF, carrying the unmet 3849-splicing mutation.
- Vertex and SpliSense Tackle CF with Novel Inhaled mRNA Approaches
- SpliSense Initiates Phase 1/2 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis
- First Clinical Trial Begins for RNA-based Therapy SPL84 for CF ,SpliSense treatment would be first for certain CF splicing mutation
- Israeli firm SpliSense moves to clinical trials for cystic fibrosis treatment
- Publication 1
- SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis, at the European Cystic Fibrosis Conference
- Corp Presentation
- Splisense raises $28.5 million in series B to advance cystic fibrosis therapy _ 2021-05-14 _ BioWorld
- Splisense raises $28.5 million in series B to advance cystic fibrosis therapy